Erschienen in:
24.08.2023 | ASO Research Letter
Current Insurance Policy Coverage for Screening Mammography in Transgender and Gender-Diverse Individuals
verfasst von:
Chandler S. Cortina, MD, MS, FSSO, FACS, Emily L. Siegel, MD, FSSO, Alexandra Polovneff, BS, Grace Sahyouni, BS, Joan M. Neuner, MD, MPH, Andrew E. Petroll, MD, MS, Melinda Stolley, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2023
Einloggen, um Zugang zu erhalten
Excerpt
A growing number of Americans identify as transgender and/or gender-diverse (TGD), defined as individuals whose gender identify is different from the sex they were assigned at birth, and these individuals face significant healthcare disparities.
1 Healthcare policies, clinical practices, and cancer screening guidelines were historically designed based on the male-female gender dichotomy and often exclude TGD persons, resulting in provider knowledge gaps and barriers to patients receiving appropriate care.
1 Breast cancer is one of the most common cancers in the United States (US), affecting 13% of cisgender women and <1% of cisgender men in their lifetime.
1,2 Screening mammography is considered the optimal breast cancer screening modality by the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS), and US federal law requires coverage by insurance providers.
2 Currently, neither the USPSTF nor the ACS provide breast cancer screening guidelines specific to TGD individuals.
1,2 …